report Archives - AudioMedica.com

Tagged: report

0
- in Oncology
- — 3 Jun, 2008
Audio Journal of Oncology Volume 16 Number 11
Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan)
Sarah Maxwell and Peter Goodwin report from: American Society of Clinical Oncology Annual Meeting, May 30-June 3, 2008, Chicago
Michael Gnant
In this edition:
1. Zoledronic …
Read more
0
- in London School of Hygiene & Tropical Medicine
- — 9 Apr, 2008
Risks From Stopping Cancer Trials Early!

Giovanni Apolone
In this edition of Audio News, presented by Peter Goodwin, Giovanni Apolone (Mario Negri Institute, Milan) and Stuart Pocock (London School of Hygiene and Tropical Medicine), talk about:
Risks From Stopping Cancer Trials Early!
– A report from
…
Read more
0
- in General Medicine
- — 27 Feb, 2008
Radio-Labelled Antibodies: Big Benefits in Follicular Lymphoma?

Timothy Illidge
Reporting From: 4th European Congress on Hematologic Malignancies, Paris 22-24 February, 2008
TIMOTHY ILLIDGE, Christie Hospital, Manchester
Radioconjugated antibodies are showing great promise for treating follicular lymphoma which has failed chemotherapy combined with rituximab. That’s according to Tim
…
Read more
0
- in Oncology
- — 27 Jan, 2008
Adjuvant Chemoradiotherapy: Big Gains In Pancreas Cancer

Charles Hsu
CHARLES HSU, Johns Hopkins University, Baltimore
Big improvements in overall survival were achieved by combining radiation with adjuvant chemotherapy for patients with pancreas cancer in a dtudy reported to the conference in Orlando. Charles Hsu told Peter Goodwin
…
Read more
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma" /> 0
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Ibritumomab Provides Benefit in Patients with Follicular Lymphoma

Anton Hagenbeek
ANTON HAGENBEEK, University Medical Centre Utrecht
For patients with advanced-stage follicular non-Hodgkinâ€™s lymphoma, ibritumomab tiuxetan seems to prolong progression free survival by two years with favourable toxicity. Sarah Maxwell spoke to study author Anton Hagenbeek at the ASH
…
Read more
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?" /> 0
- in Oncology
- — 11 Dec, 2007
Live Report from ASH:
Can Intensive Immunochemotherapy Cure Mantle Cell Lymphoma?

Christian Geisler
CHRISTIAN GEISLER, Rigshospitalet, Copenhagen
Mantle cell lymphoma, which was previously considered incurable, has apparently been cured in some patients on a phase II study. Derek Thorne got the details on the study â€“ which featured an intensive immunochemotherapy
…
Read more
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Oblimersen Extends Survival in Chronic Lymphocytic Leukemia

Susan Oâ€™Brien
SUSAN O’BRIEN, MD Anderson Cancer Center, Houston
For patients with relapsed or refractory CLL, oblimersen extends survival when added to standard fludarabine/cyclophosphamide chemotherapy. Susan Oâ€™Brien presented data from this phase III trial to the American Society of Hematology
…
Read more
Dasatinib Effective At Two Yearsâ€™ Follow Up in Chronic Phase CML" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Dasatinib Effective At Two Yearsâ€™ Follow Up in Chronic Phase CML

Richard Stone
RICHARD STONE, Dana-Farber Cancer Institute, Boston
GEORGE CANELLOS, Dana-Farber Cancer Institute
New data shows that dasatinib is giving durable responses in patients with chronic phase chronic myeloid leukemia who have failed, or who cannot tolerate imatinib. So where
…
Read more
0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH: Azacitidine â€˜New Standardâ€™ In High Risk Myelodysplastic Syndromes

Pierre Fenaux
PIERRE FENAUX, Paris 13 University
Results from a phase III study presented at ASH suggest that the hypomethylating agent azacitidine should be the new standard of care for patients with high-risk MDS. Pierre Fenaux of Paris 13 University
…
Read more
Interleukin-2 For Acute Myeloid Leukemia In First Remission?" /> 0
- in Oncology
- — 10 Dec, 2007
Live Report from ASH:
Interleukin-2 For Acute Myeloid Leukemia In First Remission?

Jonathan Kolitz
JONATHAN KOLITZ, Monter Cancer Center, Lake Success, NY
GEORGE CANELLOS, Dana-Farber Cancer Institute
For patients with acute myeloid leukemia in first remission, new data suggests that there may be a benefit from interleukin-2. Derek Thorne got the interim
…
Read more
0
- in Cardiovascular
- — 5 Nov, 2007
TRITON-TIMI 38 Prasugrel Or Clopidogrel In Percutaneous Intevention?

Gordon Tomaselli

Daniel Jones
REFERENCE: Late Breaking Clinical Trials 1, American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida
GORDON TOMASELLI, Johns Hopkins University, Baltimore
COMMENT: DANIEL JONES, President, American Heart Association, University of Mississippi, Jackson
A potential new
…
Read more
0
- in General Medicine
- — 21 Sep, 2007
BORIS: A. baumanni Highly Resistant Î²-Lactamase and Varying Susceptibility Patterns

Jennifer Lavrrar, Jane Hata, Jeanette Block
REFERENCE: Slide Session C2-1360, 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, 2007
JANE HATA, bioMÃ©rÃeux Inc, Durham
Reports from the BORIS study call for ongoing surveillance of multi-drug resistant Acinetobacter
…
Read more

Tagged: report

Sign up for AudioMedica.com news